申请人:THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE
公开号:US10703746B2
公开(公告)日:2020-07-07
Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.
公开了式 I 和式 II 的化合物及其药学上可接受的盐 本文公开了变量 A、B、Y、Z、X1、X2、R1-4 和 R13-18。这些化合物可用于治疗癌症疾病,特别是涉及突变 IDH1 酶的疾病。还公开了含有式 I 或式 II 化合物的药物组合物以及包括施用式 I 和式 II 化合物的治疗方法。
[EN] MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER<br/>[FR] INHIBITEURS D'IDH1 MUTANTS UTILES POUR TRAITER LE CANCER
申请人:US HEALTH
公开号:WO2016106331A8
公开(公告)日:2016-09-29
MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER
申请人:The United States of America,
as represented by The Secretary,
Department of Health and Human Services
公开号:EP3237385B1
公开(公告)日:2021-11-24
Discovery and Optimization of 2<i>H</i>-1λ<sup>2</sup>-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer
作者:Jason M. Rohde、Surendra Karavadhi、Rajan Pragani、Li Liu、Yuhong Fang、Weihe Zhang、Andrew McIver、Hongchao Zheng、Qingyang Liu、Mindy I. Davis、Daniel J. Urban、Tobie D. Lee、Dorian M. Cheff、Melinda Hollingshead、Mark J. Henderson、Natalia J. Martinez、Kyle R. Brimacombe、Adam Yasgar、Wei Zhao、Carleen Klumpp-Thomas、Sam Michael、Joseph Covey、William J. Moore、Gordon M. Stott、Zhuyin Li、Anton Simeonov、Ajit Jadhav、Stephen Frye、Matthew D. Hall、Min Shen、Xiaodong Wang、Samarjit Patnaik、Matthew B. Boxer